You are here

Better treatments for ANCA-associated vasculitis caused by loss of tolerance to myeloperoxidase

Autoimmune vasculitis caused by loss of tolerance to neutrophil antigens (ANCA-associated vasculitis) results in severe kidney and respiratory tract disease. There are two main autoantigens involved, myeloperoxidase (MPO) and proteinase-3. Current treatments are relatively non specific and come with significant side effects. We are an internationally recognised group researching the causes of these severe autoimmune diseases so that better markers of disease activity and relapse, and more specific and effective treatments can be developed and used. Projects in this area examine 1) how we can translate our discoveries on the parts of MPO that cause loss of tolerance into new and more effective treatments 2) extend some new models of disease using transfer of monoclonal anti-MPO antibodies, and transfer of human anti-MPO antibodies (MPO-ANCA) into humanised mice Projects will use pre-clinical mouse models of anti-MPO glomerulonephritis (ANCA-associated vasculitis) together with human blood samples from the Monash Vasculitis Registry and Biobank, led and run by Professor Kitching as part of his clinical work at Monash Health.
Essential criteria: 
Minimum entry requirements can be found here:
vasculitis, autoimmunity, myeloperoxidase, kidney disease, glomerulonephritis, tolerance
School of Clinical Sciences at Monash Health / Hudson Institute of Medical Research » Medicine - Monash Medical Centre
Available options 
Masters by research
Joint PhD/Exchange Program
Time commitment 
Top-up scholarship funding available 
Physical location 
Monash Health Translation Precinct (Monash Medical Centre)
Maliha Alikhan
Chunni Lu

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.